Brilliance ct 16 slice system

After each set of two complete chemotherapy cycles for each group, the lesion
size was monitored using CT (Brilliance CT 16-slice system; Philips Healthcare,
Andover, MA, USA) and MRI (Intera 1.5 T and Achieva 1.5 T systems; Philips
Healthcare) scanning with a scan slice thickness of 5 mm. The short-term
efficacy was evaluated after six chemotherapy cycles according to the Response
Evaluation Criteria in Solid Tumors (RECIST) guidelines and recorded as complete
response (CR), partial response (PR), stable disease, progressive disease, and
response rate (RR = CR + PR).^{11 (link)} Adverse reactions were
assessed throughout the six chemotherapy cycles according to National Cancer
Institute Common Toxicity Criteria 2.0 standards.^{12 (link)}

This retrospective study analysed data collected from consecutive paediatric patients with TFBA who attended the Department of Otolaryngology, Ningbo Women and Children’s Hospital, Ningbo, Zhejiang Province, China, between February 2012 and October 2014. All TFBAs were diagnosed by rigid bronchoscopy based on a definitive history or suspicion of foreign body inhalation. Computed tomography (CT) was performed in all patients using a Brilliance CT 16-slice system (Philips Healthcare, Best, The Netherlands) to identify any pulmonary complications.
The study was approved by the Institutional Review Board of Ningbo Women and Children’s Hospital (no. 2015012). Parents or legal guardians of the study participants provided written informed consent.